Please refer to page 10 for important disclosures and analyst certification, or on our website

www.macquarie.com/research/disclosures.

UNITED KINGDOM

BLVN LN Outperform

Price (at 15:35, 18 Jul 2014 GMT) £0.40

Valuation £ 0.75 - DCF (WACC 10.0%)

12-month target £ 0.70

12-month TSR % +73.9

GICS sector Energy

Market cap £m 130

Market cap US$m 223

30-day avg turnover £m 1.7

Number shares on issue m 324.2

Investment fundamentals Year end 30 Jun 2013A 2014E 2015E 2016E

Revenue m 0.0 0.0 0.0 0.0 EBIT m -11.1 -15.1 -21.5 -22.4 Adjusted profit m -11.1 -16.3 -21.3 -22.1 Gross cashflow m -7.8 -12.6 -18.3 -19.2 EPS adj US$ -0.04 -0.05 -0.07 -0.07 EPS adj growth % 22.8 -36.0 -28.3 -4.1

Total DPS US$ 0.00 0.00 0.00 0.00 Total div yield % 0.0 0.0 0.0 0.0 Net debt/equity % -3.5 -3.0 -24.2 -20.4

BLVN LN vs FTSE Allshare, & rec history

Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period.

Source: FactSet, Macquarie Research, July 2014

(all figures in USD unless noted, TP in GBP)

Analyst(s) David Farrell, CFA +44 20 3037 4465 david.farrell@macquarie.com Joe Stokeld +44 20 3037 4457 joe.stokeld@macquarie.com Kate Sloan +44 20 303 74453 kate.sloan@macquarie.com Giacomo Romeo, CFA +44 20 3037 4445 giacomo.romeo@macquarie.com

22 July 2014 Macquarie Capital (Europe) Limited

Bowleven Entering a New Age Event

On 24th June Bowleven farmed down its stake in the Etinde development

offshore Cameroon to New Age and LUKOIL. Although the company is now

largely financed for development, the stock continues to languish at a 22-59%

discount to the read-through valuation of the transaction. In this note we look

at why this may be and in doing so highlight the catalysts for re-rating.

Impact

Read-through valuation supportive: We estimate that post deal completion,

Bowleven will have net cash resources of 33p/sh (US$17m existing cash and

US$161m of net proceeds). Furthermore, on a fully diluted basis, the

US$170m that New Age and LUKOIL paid for a 40% stake in the Etinde

development suggests Bowleven’s residual 20% stake is worth 16p/sh.

Combined this gives a “base” valuation of 49p/sh, which could rise to an

“upside” valuation of 64p/sh if both the deferred payment and appraisal carry

are included. Our asset-by-asset bottom-up valuation is above this at 70p/sh.

Addressing issues key to closing valuation gap: We believe that bringing

in New Age and LUKOIL has de-risked the project. However there are a

number of outstanding questions that need to be answered before the

valuation gap closes, in our view. The major ones concern: commitment of the

Ferrostaal consortium to the fertiliser project; confirmation of New Age's

credentials as operator and its prioritisation of gas supply to the fertiliser plant

over competing solutions; firming up of Etinde development costs, FID timing

and first production; break-down of recoverable resources by field and how

Bowleven's capital structure will look through the development.

The stock may also benefit from near term drilling: Bowleven is entering a

period of elevated activity. By year end, it should have commenced drilling the

Bomono campaign (onshore Cameroon) targeting a net 129mboe (16p/120p).

Any discovery should hopefully be easier and quicker to commercialise than

offshore counterparts. Next year, the Etinde partners will also drill two wells to

appraise the highly prospective Intra Isongo formation, which could deliver a

net 31mmboe of upside (3p / 29p), based on our analysis.

Earnings and target price revision

Our target price falls very modestly to 70p from 71p. 2014 and 2015 (June yr

end) EPS fall 42% and 78% as we also update for 1H14 results.

Price catalyst

12-month price target: £0.70 based on a Sum of Parts methodology.

Catalyst: Signing of Gas Sale Agreement (2H14); Zingana well (10p/76p)

Action and recommendation

Not withstanding the issues above, we believe that the investment case is

more compelling now than at any point since we initiated coverage back in

December 2011 and is certainly worth another look.

Macquarie Research Bowleven

22 July 2014 2

Current share price is 22- 59% discount to transaction read-through valuation

Bowleven’s share price has increased only 1% since it announced the deal to bring in New Age

and LUKOIL to the Etinde development on 24th June. In doing so though it circumvented potential

financing problems that would have emerged if Petrofac’s IES division had chosen not to proceed

with the US$500m Strategic Alliance (as was their right at the project’s Final Investment Decision).

Under the terms of 24th June deal, Bowleven will:

Sell down a 40% interest on a fully diluted basis (50% pre government SNH back-in) in the

Etinde development to New Age (10% WI) and LUKOIL (30% WI) for a total US$170m in

cash. Bowleven will be left with 20% WI, while New Age will assume operatorship from

Bowleven with an increased 30% WI.

Receive a further US$40m staged deferred cash payment contingent upon Etinde

development Final Investment Decision (US$25m) and completion of appraisal drilling

(US$15m).

A US$40m (net) carry on two appraisal wells

The lack of movement in the share price is surprising to us given that there was a positive read-

through valuation relative to the stock price on the day of the announcement. As our calculations

below show, our base case read-through valuation is a 22% premium to the current share price

while our upside valuation is at a 59% premium.

Fig 1 Read-through valuation of New Age / LUKOIL farm-out

Source: Factset, Company data, Macquarie Research, July 2014. Based on 18 July closing price of 40.25p.

Cash portion of valuation US$m p/share Comment

Value of existing cash 17 3 June 2014 estimate. Expect results to be released in November

Value of farm-out cash 170 32 Assumes no Capital Gains Tax as per company guidance

Value of Petrofac break fee -9 -2 BLVN had said w orst case could have been US$15m

Total value of cash 178 33

Upside / (dow nside) to current share price (17%)

Asset portion of valuation

Diluted WI acquired in farm-out 40% SNH has 20% back-in rights upon FID. Headline farm-out is 50% WI

Price paid 170

Implied value of 100% licence 425 Our full f ield IM model US$740m (unrisked); US$444m (risked)

Bow leven residual stake 20% Headline residual WI is 25%

Implied value of residual stake 85 16

Base case read through valuation 263 49 No value included for Bomono, Zambia or Kenya exploration

Upside / (dow nside) to current share price 22%

Additional payments upside of valuation

Deferred payment 40 7.5 Contingent upon Etinde FID and appraisal w ell results

Value of appraisal w ell carry 40 7.5 If successful w ells likely suspended as future producers

Implied value of additional payments 80 15

Upside case read through valuation 343 64

Upside / (dow nside) to current share price 59%

Macquarie Research Bowleven

22 July 2014 3

The concerns that we believe need addressing for re-rating

Net cash proceeds: Immediately following the transaction, we believe the market worried about

the break fee payable to Petrofac for terminating the Strategic Alliance, with Bowleven saying that

it could be as high US$15m. This amount would have almost fully consumed the company’s

existing cash balance of US$17m (Macq June 2014 estimate). As it was, on 15th July Bowleven

announced a break fee of US$9m and crucially payable only after completion of the farm-out.

The second element to this is that Bowleven have said that no Capital Gains Tax is payable on the

cash proceeds. Given recent African disputes over Capital Gains Tax (Uganda) we believe there

is some lingering doubt as to whether the full US$170m cash consideration will make it into

Bowleven’s bank account. As a reference point, a 30% Capital Gains Tax on the US$170m is

worth 10p/share net to Bowleven’s cash balance. The current timing for the transaction completion

is mid September.

Ferrostaal commitment to / funding of fertiliser plant: Phase 1 of the Etinde development is to

be developed by sending gas from the IM field to a Ferrostaal run fertiliser plant and selling

associated and stripped liquids in the open market. However, as Ferrostaal and its partners are

un-listed the market has limited ongoing line of sight on their commitment to this project and

funding, although German bank KFW is known to be leading the debt financing element. It goes

without saying that unless the fertiliser plant passes FID then the Etinde development cannot. In

our view, we believe that while the formal decree of the Etinde Exploitation Authorisation is

unlikely to have an impact on sentiment towards Bowleven, the final Gas Sales Agreement

between the Etinde partners and the fertiliser consortium would. Bowleven has indicated this will

occur in 2H14 and we understand it is a major milestone towards finalising the debt for the

fertiliser project.

New Age’s credentials as operator: We believe that New Age is a relatively unknown entity to

many in the investment community, certainly at an operator level and its credentials as operator of

the Etinde development will take some time establish in our view. Below we outline some details

on both New Age and LUKOIL:

New Age: Is an African focussed E&P company based in London and run by Steve Lowden,

who is a former President of Marathon International. New Age operates the Khalakan block in

Kurdistan as well as exploration Blocks 7&8 onshore Ethiopia. Other assets include non

operated positions in Congo-Brazzaville, Somaliland and South Africa. The company is

backed (at least partially) by Kerogen Capital, which has US6$1bn invested across the oil and

gas space including investments in AJ Lucas, Buried Hill Energy and HKN.

LUKOIL: Produces 2.1% of global crude oil and holds proved oil reserves of 17.3bn barrels.

Since 2006, the company has established offshore West African footholds in Sierra Leone,

Cote D’Ivoire and Ghana. LUKOIL has an objective of increasing the gas portion of its

hydrocarbon production up to 33% from 2012 levels of 18%.

Potential slippage of fertiliser start-up and development costs: While the fertiliser plant

underpins Phase 1 of any development we believe that New Age and LUKOIL have been as

attracted by the prospective gas resources on the Etinde block (see IM Intra Isongo section later).

The Cameroon government and French company GDF Suez are proposing that additional gas

discoveries be commercialised via a greenfield Cameroon LNG development (“CLNG”). Pre-FEED

work was completed by Foster Wheeler in mid 2011 for a 3.5mtpa facility with gas supplied from

fields operated by Perenco, Noble Energy, Addax and Bowleven’s Etinde Permit. We remain

sceptical on the economic viability single train greenfield LNG development in West Africa.

However, we do see a chance that New Age waits until appraisal drilling on the Intra Isongo is

completed before sanctioning any Etinde development. That is not to say we believe that the

fertiliser plant will be usurped by LNG, but that depending upon the appraisal results an LNG

development might be more fully considered alongside the fertiliser project. Such a course of

action would allow the project to be “right sized” but also result in further slippage of the FID

Even on the Phase I development, though, we see a lack of granularity on the development costs.

Cost estimates having changed over time as the development concept evolved and in the table

below we show this. Firming up the development concept and costs will be items that come out of

the Final Investment Decision, which LUKOIL’ s farm-in press release now says will be a 2015

event . With Bowleven’s most recent guidance being a 30-month construction period between FID

and first production, we believe that mid 2018 is the appropriate time frame to have first production

against the previously implied mid 2017 guidance.

Macquarie Research Bowleven

22 July 2014 4

Fig 2 Development cost estimates and scenarios have altered over time

Source: Company data, Macquarie Research, July 2014.

In our revised modelling of the Etinde development we have made a number of assumptions

which are more conservative than current management guidance:

First production from IM in mid 2018, which is one year later than current guidance

Development costs of IM of US$900m with US$765m spend prior to first production against

current guidance of US$650-700m prior to first production (and very little thereafter)

In our upside case we model production from IE coming on-stream in mid 2021 with an

associated US$500m capex

How recoverable resources are distributed across the permit: Bowleven has historically

talked of a “hub and spoke” development, targeting various offshore fields including IM and IE and

feeding production to a central processing hub in Limbe. However, while the company has

provided recoverable resources at a group level by hydrocarbon type (FY13 net contingent

resources 263mmboe), we have yet to see the breakdown of these recoverable resources on a

field by field basis. Only in place hydrocarbons have been revealed on this basis to date and the

market therefore lacks the detail on quantum of resources attributed to each field. As far as we

know there is no need for Bowleven to publish an Independent 3rd

Party verification of resources

(Competent Persons Report) for the Gas Sales Agreement, but we do believe that completion of

one over the IM and IE fields would help alleviate some investor concerns over the resource base.

Fig 3 Etinde Permit to be developed via a “hub and spoke” approach

Source: Bowleven, July 2014. Note: Bowleven also has the IC discovery (77bcf GIIP) and Manyikeni discovery (56bcf GIIP) in MLHP-5

Will Bowleven need more equity?: As the chart below shows, Bowleven has come to the market

a number of times since 2008, raising a total US$448m in equity. The most recent raises in

October 2011 and November 2013 have been undertaken at the steepest discounts, reflecting

some investor fatigue in our view that discovered resources were not being moved into reserves.

Jun-14 Mar-13 Mar-13 Nov-12 Jan-12 Mar-11

Event Latest presentation Interim results Interim results Prelim results Capital Markets Day Interim results

Development concept IM IM / IE ? IM / IE ? Fields in MLHP-5 Hub and Spoke IE and IF

Capex - Full f ield US$300-600m

Capex - Pre first oil US$650-700m US$650-700m

Capex - Stage 1 development US$900m US$900m

Limbe Processing facilities US$275-300m

Each Hub US$75-120m

Pipelines US$1-2m/km

Final Investment Decision 4Q 2014 Mid 2014 4Q 2013 4Q 2013 4Q 2013 N/A

First production Mid 2017 2H 2016 Mid 2016 Mid 2016 Mid 2015 N/A

Macquarie Research Bowleven

22 July 2014 5

Fig 4 Bowleven’s equity raisings since 2008. Size of bubble reflects size of equity raise

Source: Company data, FactSet, Macquarie Research, July 2014.

Given the use of equity markets as a source of funding, we believe that there is some concern that

Bowleven may yet again have to revert to the markets to fund its share of development capex.

However, based on our revised field model assumptions, we believe that Bowleven’s share of

development costs prior to first production are US$153m leading to a financing shortfall of just

US$55m (assuming ongoing G&A of ~US$20mp.a.; US$10m E&A spend p.a. and the US$40m

deferred payment). This shortfall should be manageable from a debt financing position, in our

view, as it equates to a gearing ratio (ND/ND+Equity) of just 10%, with Bowleven already having

indicated that it could pursue conventional debt financing, development financing or some form of

mezzanine debt. Furthermore, if Bowleven is correct in its assumption of capex to first production,

then its financing shortfall declines to just US$42m (8% gearing).

Fig 5 Evolution of Bowleven’s net debt position

Source: Company data, Macquarie Research, July 2014. * Note: relates to Bowleven’s June year end.

-18%

-16%

-14%

-12%

-10%

-8%

-6%

-4%

-2%

0%

2%

0 50 100 150 200 250 300 350 400

Pre

m /

(dis

c) to

pre

vious d

ay (%

)

Raise price (p)

Nov-13; US$19m

Mar-08; US$78m

Oct-11; U$124m

Nov-10; US$113mJun-09; US$114m

Most recent raises have been done at the steepest discounts

17

136

111

28

-55

-100

-50

0

50

100

150

FY14e FY15e FY16e FY17e FY18e

Net c

ash

/ (

debt)

-U

S$m

Macquarie Research Bowleven

22 July 2014 6

Drilling activity that may also close the valuation gap

What potential upside is there at IM Intra Isongo level?: When appraising the Upper and

Middle Intra Isongo sands within the IM structure in 2012/13, Bowleven made a discovery within

the Intra Isongo formation. This interval flow tested at 10.8kboe/d (57% gas; 43% condensate)

from a 29m perforated section of the 70m net pay. Previously believed to be a seismic amplitude

response driven by volcanic rock, this interval can be well mapped across the Etinde permit while

potential immediately above and below the Intra Isongo (“Greater Interval”) has also been

mapped. Overall Bowleven map 1.3tcf of undiscovered gas resources within the play which, in line

with the farm-out agreement, will be appraised during 2015. It is these undiscovered resources

which are notionally earmarked to the Cameroon LNG development.

Fig 6 Mapping of Greater Intra Isongo prospectivity Fig 7 Intra Isongo resources

Source: Bowleven, Macquarie Research, July 2014 Source: Company data, Macquarie Research, July 2014

Onshore exploration success might be easier/quicker to commercialise: Bowleven recently

agreed to a farm-out of a 20% WI in its Bomono permit to Africa Fortesa Corp (“AFC”), reducing its

exposure to 80% (72% if SNH were to exercise back in rights at licence exploitation point).

Although Bowleven received no carry towards exploration costs, AFC has access to a suitable

drilling rig, which it has agreed to provide “at cost” to the Bomono partnership. As a consequence,

Bowleven will have to contribute US$13m towards the drilling of two exploration wells rather than

US$26m which would likely be the market rate. The two prospects, to be drilled in 2H14 in line

with the licence work programme commitments, are Zingana-1 and Moambe-1, which Macquarie

estimates at 114mmboe and 65mmboe recoverable each. If successful, we believe discoveries

could potentially be commercialised on a shorter time frame than the mid 2018 Etinde start-up we

model, via local power stations / industry (gas) or via the open market (liquids). Further farm-down

negotiations are also ongoing to further reduce Bowleven’s capital exposure.

Fig 8 Location of Bomono prospects Fig 9 Bomono prospective resources

Source: Bowleven, Macquarie Research, July 2014 Source: Company data, Macquarie Research, July 2014

Discovered Resources

Wet Gas Initially In Place (bcf) P90 P50 P10 Pmean

Intra Isongo 275 539 1094 626

Condensate Initially in Place (mmb) P90 P50 P10 Pmean

Intra Isongo 44 91 193 107

Prospective Resources

Wet Gas Initially In Place (bcf) P90 P50 P10 Pmean

Intra Isongo discovery horizon 303 678 1530 822

Greater Interval 296 630 1413 769

Total 599 1308 2943 1591

Condensate Initially in Place (mmb) P90 P50 P10 Pmean

Intra Isongo discovery horizon 48 114 269 141

Greater Interval 47 107 248 132

Total 95 221 517 273

Zingana-1

Hydrocarbons Initially in

Place

Oil

(mmb)

Associated

Gas (bcf)

Gas

(bcf)

Condensate

(mmb)

Total

(mmboe)

Tertiary D&E sands 302 224 339

Tertiary B&C sands 196 7 40

Macq Recovery Factor 20% 75% 75% 20%

Recoverable 60 168 147 1 114

Moambe-1

Hydrocarbons Initially in

Place

Oil

(mmb)

Associated

Gas (bcf)

Gas

(bcf)

Condensate

(mmb)

Total

(mmboe)

Tertiary D&E sands 176 80 189

Tertiary B&C sands 153 4 30

Macq Recovery Factor 20% 75% 75% 20%

Recoverable 35 60 115 1 65

Macquarie Research Bowleven

22 July 2014 7

Valuation: Outperform maintained; TP trimmed very slightly to 70p

We have updated our valuation for Bowleven, removing the impact of the Petrofac Strategic

Alliance on the cash-flows of the Etinde development. Instead these are replaced by more

conventional 20% WI obligation for Bowleven. Furthermore, we have added risked E&A upside

pertaining to the two upcoming exploration wells on the Bomono permit (BLVN 80% WI) and also

the upside that could come from appraising the Intra Isongo now that a two-well appraisal

campaign is funded via the farm-out.

The table below shows the major impacts that this has on our valuation:

Overall our Core NAV falls by 39% to 44p, although clearly this is a firmer Core NAV with 33p

of net cash against just 5p previously. The reason for the decline is i) the reduction in

Bowleven’s Working Interest in the Etinde Permit and ii) with the monetisation route for the IE

field still lacking clarity, we have moved this former component of Core NAV into Risked E&A

upside.

We include IE in Risked E&A upside with a 50% Chance of Success (8p/15p) as well as the

Zingana (10p / 76p) and Maombe (5p /44p) Bomono prospects and 153mmboe Intra Isongo

prospective resources risked at 10% (3p / 29p).

Fig 10 Bowleven’s Core and Total NAV; components of target price highlighted

Source: Company data, Macquarie Research, July 2014

Bowleven Previous published

Unit Value

(US$/boe)

EMV

(US$m)

Value

(p/sh) Change

Value

(p/sh) Comments

Assets (NPV10)

Producing Assets 0 na 0 0p 0p 0% 0p

Net Cash/(Net Debt) na 178 33p 28p 537% 5p June 2014 forecast and net farm-out proceeds of US$161m

Undeveloped Assets 13 6.1 81 15p -54p -78% 70p Removal of IE, and IM first gas pushed back to mid 2018

Other assets less G&A -25 -5p -1p -34% -4p

Core NAV 13 17.7 234 44p -28p -39% 71p

Option Proceeds 19 3p 0p 8% 3p

Risked E&A upside 38 3.9 151 28p 11p 65% 17p Inclusion of IE discovery

Total NAV 403 75p -16p -18% 92p

Risked E&A upside included in TP 26p 26p nmf 0p IE discovery, IM Intra Isongo upside, Bomono prospects

Unrisked value of above 164p 164p nmf 0p

Target Price 70p -1p -2% 71p

Risked

resources

(mmboe)

Macquarie Research Bowleven

22 July 2014 8

Fig 11 Bowleven’s EMV Breakdown: Components of Risked E&A included in target price highlighted

Source: Company data, Macquarie Research, July 2014

Country Project/Prospect Licence Gross Res.

Potential

(mmboe)

Working

Interest

(%)

Costs

Paid

(%)

C.O.S.

(%)1

Discounted

Value

(US$/boe)2

Net Risked

(mmboe)

EMV

(US$m)3

Risked

Value

(p/sh)

Unrisked

Value

(p/sh)4

Producing Assets

0 0 0 0 0

Undeveloped assets

Cameroon Phase 1 - IM MLHP-7 110 20% 0% 60% $6.1 13 81 15 25

110 13 81 15 25

Risked Upside

Cameroon Phase 1 - IE MLHP-7 39 20% 0% 50% $10.6 4 41 8 15

Cameroon Zingana-1 Bomono 114 72% 80% 15% $5.0 12 55 10 76

Cameroon Moambe-1 Bomono 65 72% 80% 15% $5.0 7 29 5 44

Cameroon Intra-Isongo (IM) MLHP-7 153 20% 0% 10% $5.0 3 15 3 29

Cameroon IF MLHP-7 53 20% 60% 5% $0.0 1 0 0 0

Cameroon Lower Omicron MLHP-5 29 20% 75% 15% $1.4 1 0 0 2

Cameroon Deep Omicron MLHP-5 47 20% 75% 15% $4.9 1 0 0 9

Cameroon Epsilon MLHP-5 61 20% 75% 15% $4.9 2 0 0 11

Cameroon Deep Omicron (upside) MLHP-5 120 20% 75% 15% $4.9 4 5 1 22

Cameroon Epsilon (Upside) MLHP-5 30 20% 75% 15% $4.9 1 4 1 6

Kenya Generic prospect 11B 100 20% 100% 15% $3.5 3 0 0 13

811 38 151 28 226

Total Asset Value 921 52 232 43 252

Notes Bowleven outstanding shares (fd) 335

1. C.O.S. - Chances of Success - Includes all risk factors such as geological, political, project delivery, commercial, etc. GBP/USD 1.6

2. Value/boe - Includes proximity to established infrastructure, development capex required, oil quality, discount rate (10%), etc.

3. EMV - Expected Monetary Value - a risk weighted value. EMV = (Reward*C.O.S.) - [Capital at Risk*(1-C.O.S.)]

4. Unrisked Value - Refers to the value that could potentially be realized if success was achieved on prospect and commercial production realized.

Macquarie Research Bowleven

22 July 2014 9

BOWLEVEN (BLVN, Outperform, Target price: 70p)

Price Assumption 2012A 2013A 2014E 2015E 2016E Half-yearly Forecast H2/13A H1/14A H2/14E H1/15E H2/15E

Oil-Brent $/b 112.31 108.86 108.74 114.50 115.00 Oil-Brent $/b 107.96 109.52 107.96 114.00 115.00

Gas-UK p/therm 57.59 63.77 65.82 63.47 65.34 Gas-UK US$/mmbtu 10.2 10.8 9.9 9.9 9.9

Gas-UK US$/mmbtu 9.48 10.00 10.35 10.41 10.66

US$/£ (period average) $ 1.58 1.57 1.61 1.60 1.60

Oil & Liquids kb/d 0.0 0.0 0.0 0.0 0.0

Natural Gas mmcf/d 0.0 0.0 0.0 0.0 0.0

Total Production kboe/d (@ 6:1) 0.0 0.0 0.0 0.0 0.0

Income Statement 2012A 2013A 2014E 2015E 2016E

Oil & Liquids kb/d 0.0 0.0 0.0 0.0 0.0 Revenue (net of hedging & transp.) m 0.0 0.0 0.0 0.0 0.0

Natural Gas mmcf/d 0.0 0.0 0.0 0.0 0.0 EBITDA m (4.8) (5.5) (9.7) (10.7) (10.7)

Total Production kboe/d (@ 6:1) 0.0 0.0 0.0 0.0 0.0 Net Income m (1.7) (6.6) (9.6) (10.7) (10.6)

Gas Production Ratio % na na na na na Adjusted EPS (diluted) cts/sh (0.6) (2.1) (3.0) (3.3) (3.3)

Cash Flow from Operations m (0.0) (4.4) (8.2) (9.2) (9.1)

Production Growth YoY % nmf nmf nmf nmf nmf

Gross Revenue (pre-royalty) m 0 0 0 0 0 Production profile 2012A 2013A 2014E 2015E 2016E

Royalties m 0 0 0 0 0 Gas kboe/d 0.0 0.0 0.0 0.0 0.0

Net Revenue m 0 0 0 0 0 Oil kboe/d 0.0 0.0 0.0 0.0 0.0

Operating Costs m 0 0 0 0 0 Total kboe/d 0.0 0.0 0.0 0.0 0.0

G&A Costs m -8 -9 -13 -19 -20 % gas % 0% 0% 0% 0% 0%

Other operating expenses m -9 -2 -2 -2 -2

EBITDA m -16 -11 -15 -21 -22

DD&A m 0 0 0 0 0

Interest Costs m 3 0 -1 0 0

Taxes m 0 0 0 0 0

Other Non-Cash Costs m 0 0 0 0 0

Net Income m -13 -11 -16 -21 -22

EPS (basic) cts/sh -4.9 -3.8 -5.1 -6.6 -6.8

EPS (diluted) cts/sh -4.9 -3.8 -5.1 -6.6 -6.8

Adjusted EPS (diluted) cts/sh -4.9 -3.8 -5.1 -6.6 -6.8

Revenue per Share Growth YoY % nmf nmf nmf nmf nmf

EBITDA per Share Growth YoY % nmf nmf nmf nmf nmf

Basic Shares (WA / OS) m 266.9 294.7 316.8 324.2 324.2

Diluted Shares (WA / OS) m 277.6 305.3 327.5 334.9 334.9

Balance Sheet 2012A 2013A 2014E 2015E 2016E Cashflow Analysis 2012A 2013A 2014E 2015E 2016E

Cash (including Restricted) m 142.5 19.7 17.2 136.5 111.3 Cash Flow from Operations m (10.0) (8.4) (12.3) (18.3) (19.2)

Debt m 0.0 0.0 0.0 0.0 0.0 Chgs in Working Cap m (5.6) 0.5 (0.2) 0.0 0.0

Convertible debt m 0.0 0.0 0.0 0.0 0.0 Net Cash Flow from Operations m (15.6) (7.8) (12.6) (18.3) (19.2)

Net Debt (Cash) m -142.5 -19.7 -17.2 -136.5 -111.3 Cash Flow from Investing m (58.7) (114.4) (15.2) 137.6 (6.0)

Cash Flow from Financing m 120.1 (0.5) 25.3 0.0 0.0

Total Assets m 588.0 585.6 589.2 570.4 550.7 Increase in Cash m 45.8 (122.7) (2.5) 119.3 (25.2)

Total Liabilities m 8.6 15.6 6.3 6.3 6.3

Total S/H Equity m 579.4 570.0 582.8 564.0 544.4 Free Cash Flow1 m (74.3) (117.2) (27.8) 119.3 (25.2)

Debt Adjusted Cash Flow (DACF) m (5.1) (9.4) (12.2) (18.5) (19.5)

Ratios Analysis 2012A 2013A 2014E 2015E 2016E

ROA % -2.4 -1.9 -2.8 -3.7 -3.9 CFPS (diluted) cts/sh (5.6) (2.6) (3.8) (5.5) (5.7)

ROCE % -0.3 -0.4 -0.5 -0.7 -0.7

ROE % -1.8 -1.4 -2.1 -2.7 -2.8 Capital Expenditures & Acquisitions m 58.7 109.4 15.2 -137.6 6.0

Net Debt/Equity % -24.6 -3.5 -3.0 -24.2 -20.4

Net Debt/CF x 9.1 2.5 1.4 7.4 5.8 Capex/Cash Flow x (5.9) (13.1) (1.2) 7.5 (0.3)

Price/Book x 0.3 0.3 0.4 0.4 0.4

Book Value $/sh 2.0 1.9 1.8 1.7 1.7

Valuation 2012A 2013A 2014E 2015E 2016E Per Boe Statistics 2012A 2013A 2014E 2015E 2016E

P/E x nmf nmf nmf nmf nmf Revenue/boe $/boe nmf nmf nmf nmf nmf

P/CF x nmf nmf nmf nmf nmf Royalties/boe $/boe nmf nmf nmf nmf nmf

Dividend Yield % 0.0 0.0 0.0 0.0 0.0 Operating costs/boe $/boe nmf nmf nmf nmf nmf

Enterprise Value m 340 283 273 86 111 Operating Netback/boe $/boe 0.0 0.0 0.0 0.0 0.0

EV/DACF x -66.3 -30.0 -22.3 -4.6 -5.7 G&A/boe $/boe nmf nmf nmf nmf nmf

EV/Reserves2 $/boe nmf Interest/boe $/boe nmf nmf nmf nmf nmf

EV/2P + 2C $/boe 1.2 Cash Tax/boe $/boe nmf nmf nmf nmf nmf

EV/Production $k/boe/d nmf nmf nmf nmf nmf Cash Netback/boe $/boe 0.0 0.0 0.0 0.0 0.0

Reserve/Production (2P) years nmf nmf nmf nmf nmf Depletion and Depreciation/boe $/boe nmf nmf nmf nmf nmf

Stock based compensation/boe $/boe nmf nmf nmf nmf nmf

Core Net Asset Value (PV10AT) 2 p/sh Other Non-cash/boe $/boe nmf nmf nmf nmf nmf

P/CoreNAV x Deferred Taxes/boe $/boe nmf nmf nmf nmf nmf

Core NAV + Risked Resource Upside 3 p/sh Exceptionals/boe $/boe nmf nmf nmf nmf nmf

P/RENAV x Earnings Netback/boe $/boe 0.0 0.0 0.0 0.0 0.0

All figures US$ unless noted and production and reserve figures are gross of royalties

1) Cash flow from Operations (before chg in WC) Less Capex

2) Excludes non-producing assets

3) Risked resource upside based on LT price of US$11.04/mmbtu HH, US$115/b Brent, and GBP/USD 1.6

Source: Company Data, Macquarie Research, July 2014

0.0 0.0 0.0 0.0 0.0 0.0 0.0

2.6

5.1 5.2

0%

20%

40%

60%

80%

100%

0

1

2

3

4

5

6

2011A

2012A

2013A

2014E

2015E

2016E

2017E

2018E

2019E

2020E

kboe/d

Gas Oil % gas

Macquarie Research Bowleven

22 July 2014 10

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield

Macquarie – Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie First South - South Africa Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - USA Outperform (Buy) – return >5% in excess of Russell 3000 index return Neutral (Hold) – return within 5% of Russell 3000 index return Underperform (Sell)– return >5% below Russell 3000 index return

Volatility index definition*

This is calculated from the volatility of historical price movements. Very high–highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative. High – stock should be expected to move up or

down at least 40–60% in a year – investors should be aware this stock could be speculative. Medium – stock should be expected to move up or down at least 30–40% in a year. Low–medium – stock should be expected to move up or down at least 25–30% in a year. Low – stock should be expected to move up or down at least 15–25% in a year. * Applicable to Asia/Australian/NZ/Canada stocks only

Recommendations – 12 months Note: Quant recommendations may differ from Fundamental Analyst recommendations

Financial definitions

All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests EPS = adjusted net profit / efpowa* ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions – For quarter ending 30 June 2014

AU/NZ Asia RSA USA CA EUR Outperform 51.67% 60.69% 34.67% 42.33% 55.41% 44.84% (for US coverage by MCUSA, 6.76% of stocks followed are investment banking clients)

Neutral 33.00% 23.93% 38.67% 50.92% 38.51% 35.87% (for US coverage by MCUSA, 7.25% of stocks followed are investment banking clients)

Underperform 15.33% 15.38% 26.67% 6.75% 6.08% 19.28% (for US coverage by MCUSA, 0.48% of stocks followed are investment banking clients)

BLVN LN vs FTSE 100, & rec history

(all figures in GBP currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period.

Source: FactSet, Macquarie Research, July 2014

12-month target price methodology

BLVN LN: £0.70 based on a Sum of Parts methodology

Company-specific disclosures: Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures.

Date Stock Code (BBG code) Recommendation Target Price 10-Jan-2014 BLVN LN Outperform £.71 19-Jul-2013 BLVN LN Outperform £1.00 21-Mar-2013 BLVN LN Neutral £1.06 06-Dec-2012 BLVN LN Neutral £.89 13-Jul-2012 BLVN LN Neutral £.96 27-Mar-2012 BLVN LN Neutral £1.10 06-Jan-2012 BLVN LN Outperform £1.35 21-Dec-2011 BLVN LN Neutral £1.10

Target price risk disclosures: BLVN LN: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Macquarie Research Bowleven

22 July 2014 11

Analyst certification: The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062) (MGL) and its related entities (the Macquarie Group) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. General disclaimers: Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie First South Securities (Pty) Limited; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Country-specific disclaimers: Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Securities Ltd, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Securities Ltd. Japan: In Japan, research is issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Securities Exchange Co. Ltd (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association and The Financial Futures Association of Japan and Japan Investment Advisers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt Ltd. (CIN: U67120MH1995PTC089592), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India, which is a SEBI registered Stock Broker having membership with National Stock Exchange of India Limited (INB231246738) and Bombay Stock Exchange Limited (INB011246734). Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Thailand: In Thailand, research is produced with the contribution of Kasikorn Securities Public Company Limited, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. Macquarie Securities (Thailand) Limited and Kasikorn Securities Public Company Limited have entered into an exclusive strategic alliance agreement to broaden and deepen the scope of services provided to each parties respective clients. The strategic alliance does not constitute a joint venture. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thai-iod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03053&pageDiv=02. South Africa: In South Africa, research is issued and distributed by Macquarie First South Securities (Pty) Limited, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie First South Securities (Pty) Limited and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report

Macquarie Research Bowleven

22 July 2014 12

prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.’s affiliate’s analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group Auckland

Tel: (649) 377 6433

Jakarta Tel: (62 21) 515 1818

Munich Tel: (089) 2444 31800

Sydney Tel: (612) 8232 9555

Bangkok

Tel: (662) 694 7999

Johannesburg Tel: (2711) 583 2000

New York Tel: (1 212) 231 2500

Taipei Tel: (886 2) 2734 7500

Calgary

Tel: (1 403) 294 9541

Kuala Lumpur Tel: (60 3) 2059 8833

Paris Tel: (33 1) 7842 3823

Tokyo Tel: (81 3) 3512 7900

Denver

Tel: (303) 952 2800

London Tel: (44 20) 3037 2000

Perth Tel: (618) 9224 0888

Toronto Tel: (1 416) 848 3500

Frankfurt

Tel: (069) 509 578 000

Manila Tel: (63 2) 857 0888

Seoul Tel: (82 2) 3705 8500

Vancouver Tel: (1 604) 605 3944

Geneva

Tel: (41) 22 818 7777

Melbourne Tel: (613) 9635 8139

Shanghai Tel: (86 21) 6841 3355

Hong Kong

Tel: (852) 2823 3588

Mumbai Tel: (91 22) 6653 3000

Singapore Tel: (65) 6601 1111

Available to clients on the world wide web at www.macquarieresearch.com and through Thomson Financial, FactSet, Reuters, Bloomberg, and CapitalIQ.

EMEA Research Heads of Equity Research

John O’Connell (Global) (612) 8232 7544 Shai Hill (Europe) (44 20) 3037 4232 George Brits (South Africa) (2711) 583 2223

Consumer Staples

Food & Beverages Sreedhar Mahamkali (London) (44 20) 3037 4016

Consumer Discretionary

Retailing Sreedhar Mahamkali (London) (44 20) 3037 4016 Charlie Storey (London) (44 20) 3037 2327 David Smith (Johannesburg) (2711) 583 2248

Energy

David Farrell (London) (44 20) 3037 4465 Giacomo Romeo (London) (44 20) 3037 4445 Joe Stokeld (London) (44 20) 3037 4457 Aditya Suresh (Hong Kong) (852) 3922 1265 Gerhard Engelbrecht (Johannesburg) (2711) 583 2407

Alternative Energy & Utilities

Shai Hill (Europe) (44 20) 3037 4232 Dominic Nash (Europe) (44 20) 3037 4239 Jose Ruiz (Europe) (44 20) 3037 1912 Peter Crampton (Europe) (44 20) 3037 4559

Financials

Diversified Financials Elan Levy (Johannesburg) (27 11) 583 2165 Neil Welch (London) (44 20) 3037 4272

Banks Edward Firth (Europe) (44 20) 3037 4077 Benjie Creelan-Sandford (London) (44 20) 3037 4081 Thomas Stoegner (London) (44 20) 3037 4172 Piers Brown (London) (44 20) 3037 4044 Patrick Lee (London) (44 20) 3037 4482 Chantal Sirisena (London) (44 20) 3037 2190 Charles Russell (Johannesburg) (27 11) 583 2326

Insurance Neil Welch (London) (44 20) 3037 4272

Industrials

Capital Goods Rowan Goeller((Johannesburg) (2711) 583 2131

Autos Christian Breitsprecher (Frankfurt) (49 69) 50957 8014 Jens Schattner (Frankfurt) (49 69) 50957 8026

Transportation – Infrastructure Robert Joynson (London) (44 20) 3037 4240 Rowan Goeller((Johannesburg) (2711) 583 2131

Materials

Chemicals/Containers, Packaging/Paper & Forest Products, Construction Materials Rowan Goeller((Johannesburg) (2711) 583 2131 Christian Faitz (Frankfurt) (49 69) 50957 8017 Al Kabili (New York) (1 212) 231 0683

Global Metals & Mining Jeff Largey (London) (44 20) 3037 4359 Alon Olsha (London) (44 20) 3037 2637 Jeremy Dibb (London) (44 20) 3037 5481 Daniel Lurch (London) (44 20) 3037 5329 Kieran Daly (Johannesburg) (2711) 583 2208 James Oberholzer (Johannesburg) (2711) 583 2367 Richard Hart (Johannesburg) (2711) 583 2320 Gerhard Engelbrecht (Johannesburg) (27 11) 583 2407 Adrian Wood (Sydney) (612) 8232 8531

Pharmaceuticals

Ada Li (Johannesburg) (2711) 583 2181

Real Estate

Property Trusts & Developers Leon Allison (Johannesburg) (2711) 583 2209

TMET

Telecommunications Guy Peddy (London) (44 20) 3037 4509

Media Tim Nollen (New York) (1 212) 231 0635 Angus Tweedie (London) (44 20) 3037 4099

Commodities & Precious Metals

Colin Hamilton (Global) (44 20) 3037 4061 Jim Lennon (London) (44 20) 3037 4271 Matthew Turner (London) (44 20) 3037 4340 Stefan Ljubisavljevic (London) (44 20) 3037 4247 Chris Gadd (London) (44 20) 3037 1957 Vivienne Lloyd (London) (44 20) 3037 4530 Yubin Fu (London) (44 20) 3037 2622 Daryna Kovalska (London) (44 20) 3037 2732 Graeme Train (Shanghai) (86 21) 2412 9035 Angela Bi (Shanghai) (86 21) 2412 9086

European Macro Group

Economics & Strategy Daniel McCormack (Europe) (44 20) 3037 4276 Elna Moolman (Johannesburg) (2711) 583 2570

Strategy George Brits (South Africa) (2711) 583 2223

Quantitative Gurvinder Brar (Global) (44 20) 3037 4036 Giuliano De Rossi (London) (44 20) 3037 1997 Ioan Mirciov (London) (44 20) 3037 1939 Inez Khoo (London) (44 20) 3037 2640 Josiah Rudolph (Johannesburg) (2711) 583 2210

Find our research at

Macquarie: www.macquarie.com.au/research

Thomson: www.thomson.com/financial

Reuters: www.knowledge.reuters.com

Bloomberg: MAC GO

Factset: http://www.factset.com/home.aspx

CapitalIQ www.capitaliq.com

Contact Gareth Warfield for access (612) 8232 3207

Email addresses

FirstName.Surname@macquarie.com

eg. john.oconnell@macquarie.com

Equities

Stevan Vrcelj (Global Head) (612) 8232 5999

Julian Wentzel (Europe) (44 20) 3037 4274 Sarah-Jane Wagg (Johannesburg) (2711) 583 2000

European Execution Services

Anthony Bray (London) (44 20) 3037 4603 Robert Tappin (London) (44 20) 3037 4827 Marc Crome (London) (44 20) 3037 4778 Wayne Drayton (London) (44 20) 3037 4980 James Buckley (London) (44 20) 3037 4750 Jim Dixon (London) (44 20) 3037 4949 KC O'Rourke (London) (44 20) 3037 4910 Danny Want (London) (44 20) 3037 4847 Peter Homan (London) (44 20) 3037 4740 Gregorio Esmelian (London) (44 20) 3037 4973 Will Rogers (London) (44 20) 3037 1721 Richard McGlashan (London) (44 20) 3037 4824 Andreas Bergmann (London) (44 20) 3037 4680 Robert Lenihan (London) (44 20) 3037 4908 Richard Bateson (London) (44 20) 3037 4821 David Hemming (London) (44 20) 3037 4909 NicK Bryan (London) (44 20) 3037 4768 JC Coetzee (London) (44 20) 3037 4969 George Sampson (London) (44 20) 3037 1732 Katie Ramsey (London) (44 20) 3037 4919

ETF Trading

Robin Quinnell (London) (44 20) 3023 8885

Miller Guo (London) (44 20) 3023 8886 Ed Robinson (New York) (1 212) 231 0960

US Sales Trading

Chris Reale (New York) (1 212) 231 2555

EU Cash Sales

Sam Bygott-Webb (London) (44 20) 3037 4767

Richard Alderman (London) (44 20) 3037 4875 Luke Ahern (London) (44 20) 3037 4960 Charles Lesser (London) (44 20) 3037 4771 James Lumby (London) (44 20) 3037 4846 Awais Khan (London) (44 20) 3037 4967 Duncan Farr (London) (44 20) 3037 4869 James Stearns (London) (44 20) 3037 4933 Roger Lee (London) (44 20) 3037 4954 Joanna Thompson (London) (44 20) 3037 4925 Claire Elsdon (London) (44 20) 3037 4787 Markus Geisbuesch (Frankfurt) (49 69) 50957 8709 Holger Hoepfner (Geneva) (41 22) 818 7777

Martin Pommier (New York) (1 212) 231 8054 Jan Halaska (Boston) (1 617) 598 2503 Chris Carr (New York) (1 212) 231-6398 Doug Stone (New York) (1 212) 231 2606 Jessica London (New York) (1 212) 231 0977

South Africa Sales

Franco Lorenzani (Johannesburg) (2711) 583 2014

Sven Forssman (Johannesburg) (2711) 583 2369 Ed Southey (Johannesburg) (2711) 583 2026 Jesse Ushewokunze (New York) (1 212) 231 2504

South Africa Sales Trading

Harry Ioannou (Johannesburg) (2711) 583 2015

Keith Thompson (Johannesburg) (2711) 583 2058 Martin Hughes (Johannesburg) (2711) 583 2019 Marcello Damilano (Johannesburg) (2711) 583 2018 Roland Wood (Cape Town) (2721) 813 2611

Commodity Hedge Fund Sales

Chris Looney (New York) (1 212) 231 0836

Iain Lindsay (London) (44 20) 3037 4825 Guy Keller (Singapore) (65) 6601 0303

Commodity Corporate Sales

Nael Noueiri (London) (44 20) 3037 4913 Rohan Khurana (Singapore) (65) 6601 0308

Commodity Investor Products

Arun Assumall (London) (44 20) 3037 4953

Catherine Littlefield (New York) (1 212) 231 6348